Pleiotropic effects of transforming growth factor-β in hematopoietic stem-cell transplantation

Transplantation

Volumn 90, Issue 11, 2010, Pages 1139-1144

  Coomes, Stephanie M ^a   Moore, Bethany B ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Acute graft versus host disease; Chronic GVHD; Infection; T regulatory cells

Indexed keywords

HALOFUGINONE; INTERLEUKIN 2; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

BONE MARROW TRANSPLANTATION; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CYTOKINE PRODUCTION; GRAFT RECIPIENT; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LUNG FIBROSIS; LUNG INFECTION; NATURAL KILLER CELL; NONHUMAN; ORGAN INJURY; OUTCOME ASSESSMENT; PLEIOTROPY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

ANIMALS; CELL SURVIVAL; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; PULMONARY FIBROSIS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 78650307077     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181efd018     Document Type: Review

References (67)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813.
2. Afessa B, Peters SG. Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med 2006; 27: 297.
3. Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004; 170: 22.
4. Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet 2009; 373: 1550.
5. Liem LM, Fibbe WE, van Houwelingen HC, et al. Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation 1999; 67: 59.
6. Malone FR, Leisenring WM, Storer BE, et al. Prolonged anorexia and elevated plasma cytokine levels following myeloablative allogeneic hematopoietic cell transplant. Bone Marrow Transplant 2007; 40: 765.
7. Panoskaltsis-Mortari A, Taylor PA, Yaeger TM, et al. The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamide. J Clin Invest 1997; 100: 1015.
8. Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24: 99.
9. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood) 2008; 233: 109.
10. Wu JM, Thoburn CJ, Wisell J, et al. CD20, AIF-1, and TGF-beta in graft-versus-host disease: A study of mRNA expression in histologically matched skin biopsies. Mod Pathol 2010; 23: 720.
11. Anscher MS, Kong FM, Jirtle RL. The relevance of transforming growth factor beta 1 in pulmonary injury after radiation therapy. Lung Cancer 1998; 19: 109.
12. Coomes SM, Wilke CA, Moore TA, et al. Induction of TGF-beta 1, not regulatory T cells, impairs anti-viral immunity in the lung following bone marrow transplant. J Immunol 2010; 184: 5130.
13. Govinden R, Bhoola KD. Genealogy, expression, and cellular function of transforming growth factor-beta. Pharmacol Ther 2003; 98: 257.
14. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003; 116(pt 2): 217.
15. Gentry LE, Nash BW. The pro domain of pre-pro-transforming growth factor beta 1 when independently expressed is a functional binding protein for the mature growth factor. Biochemistry 1990; 29: 6851.
16. Yu Q, Stamenkovic I. Cell surface-localized matrix met alloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14: 163.
17. Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96: 319.
18. Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol 1988; 106: 1659.
19. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753.
20. Wahl SM. Transforming growth factor-beta: Innately bipolar. Curr Opin Immunol 2007; 19: 55.
21. Adams DH, Hathaway M, Shaw J, et al. Transforming growth factor-beta induces human T lymphocyte migration in vitro. J Immunol 1991; 147: 609.
22. Kehrl JH, Wakefield LM, Roberts AB, et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986; 163: 1037.
23. Ludviksson BR, Seegers D, Resnick AS, et al. The effect of TGF-beta1 on immune responses of naive versus memory CD4 + Th1/Th2 T cells. Eur J Immunol 2000; 30: 2101.
24. Gorelik L, Fields PE, Flavell RA. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J Im-munol2000; 165: 4773.
25. Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24: 179.
26. + regulatory T cells by TGFbeta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875.
27. Afzali B, Mitchell P, Lechler RI, et al. Translational mini-review series on Th17 cells: Induction of interleukin-17 production by regulatory T cells. Clin Exp Immunol 2009; 159: 120.
28. Cazac BB, Roes J. TGF-beta receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 2000; 13: 443.
29. Borsutzky S, Cazac BB, Roes J, et al. TGF-beta receptor signaling is critical for mucosal IgA responses. J Immunol 2004; 173: 3305.
30. Brandes ME, Mai UE, Ohura K, et al. Type I transforming growth factor-beta receptors on neutrophils mediate chemotaxis to transforming growth factor-beta. J Immunol 1991; 147: 1600.
31. Wahl SM, Hunt DA, Wakefield LM, et al. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987; 84: 5788.
32. Tsunawaki S, Sporn M, Ding A, et al. Deactivation of macrophages by transforming growth factor-beta. Nature 1988; 334: 260.
33. Rook AH, Kehrl JH, Wakefield LM, et al. Effects of transforming growth factor beta on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986; 136: 3916.
34. O'Connor RA, Taams LS, Anderton SM. Translational mini-review series on Th17 cells: CD4 T helper cells: Functional plasticity and differential sensitivity to regulatory T cell-mediated regulation. Clin Exp Immunol 2009; 159: 137.
35. Toubai T, Sun Y, Reddy P. GVHD pathophysiology: Is acute different from chronic? Best Pract Res Clin Haematol 2008; 21: 101.
36. Visentainer JE, Lieber SR, Persoli LB, et al. Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp Hematol 2003; 31: 1044.
37. Banovic T, MacDonald KP, Morris ES, et al. TGF-beta in allogeneic stem cell transplantation: Friend or foe? Blood 2005; 106: 2206.
38. Asai O, Longo DL, Tian ZG, et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 1998; 101: 1835.
39. Mou HB, Lin MF, Cen H, et al. Prevention of murine acute graft-versus-host disease by recipient-derived TGFbeta1-treated dendritic cells. Transplant Proc 2004; 36: 1604.
40. Martin PJ. Biology of chronic graft-versus-host disease: Implications for a future therapeutic approach. Keio J Med 2008; 57: 177.
41. Pines M, Snyder D, Yarkoni S, et al. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 2003; 9: 417.
42. + T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 2004; 104: 1565.
43. Fahlen L, Read S, Gorelik L, et al. T cells that cannot respond to TGF-beta escape control by CD4( + )CD25( + ) regulatory T cells. JExp Med 2005; 201: 737.
44. Baron C, Somogyi R, Greller LD, et al. Prediction of graft-versus-host disease in humans by donor gene-expression profiling. PLoSMed 2007; 4: e23.
45. Miura Y, Thoburn CJ, Bright EC, et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004; 104: 2187.
46. + regulatory T cells. Blood 2007; 110: 3793.
47. Chen X, Vodanovic-Jankovic S, Johnson B, et al. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 2007; 110: 3804.
48. Hinz B, Celetta G, Tomasek JJ, et al. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell 2001; 12: 2730.
49. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Update on defibrotide and other current investigational therapies. Bone Marrow Transplant 2008; 41:229.
50. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. NEnglJMed 1994; 331: 1286.
51. Anscher MS, Peters WP, Reisenbichler H, et al. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. NEnglJMed 1993; 328: 1592.
52. McCormick LL, Zhang Y, Tootell E, et al. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: A model for human scleroderma. J Immunol 1999; 163: 5693.
53. Marks LB, Yu X, Vujaskovic Z, et al. Radiation-induced lung injury. Semin Radiat Oncol 2003; 13: 333.
54. Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for severe aplastic anemia: A randomized controlled study of conditioning regimens. Blood 2007; 109: 4582.
55. Desmarets M, Cadwell CM, Peterson KR, et al. Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model. Blood 2009; 114: 2315.
56. + regulatory T cells. Proc Natl Acad Sci USA 2006; 103: 5460.
57. Afessa B, Peters SG. Noninfectious pneumonitis after blood and marrow transplant. Curr Opin Oncol 2008; 20: 227.
58. Adler H, Beland JL, Kozlow W, et al. A role for transforming growth factor-beta1 in the increased pneumonitis in murine allogeneic bone marrow transplant recipients with graft-versus-host disease after pulmonary herpes simplex virus type 1 infection. Blood 1998; 92: 2581.
59. + regulatory T cell function. Eur J Immunol 2004; 34: 2996.
60. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4( + )CD25( + ) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493.
61. + immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transplant 2002; 8: 525.
62. Coghill JM, Carlson MJ, Moran TP, et al. The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting. Leuk Lymphoma 2008; 49: 1860.
63. Nguyen VH, ShashidharS, Chang DS, et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood 2008; 111: 945.
64. Ogawa Y, Dogru M, Uchino M, et al. Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD. Bone Marrow Transplant 2009; 45: 565.
65. Booth AJ, Csencsits-Smith K, Wood SC, et al. Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection. Am J Transplant 2010; 10: 220.
66. Chuang-Tsai S, Sisson TH, Hattori N, et al. Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1. Am J Pathol 2003; 163: 445.
67. Gruber BL, Marchese MJ, Kew RR. Transforming growth factor-beta 1 mediates mast cell chemotaxis. J Immunol 1994; 152: 5860.